Novartis gets FDA approval for skin cancer drug combination
Advertisement
Novartis AG said on Friday it received the U.S. Food and Drug Administration's regular approval for a drug combination to treat an aggressive form of skin cancer.
The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based on two years overall survival in patients, the company said.
The combination was initially approved based on mid-stage data through the FDA's accelerated approval program, but the approval was contingent on data from late-stage trial.
Tafinlar and Mekinist are among cancer drugs Novartis had purchased from GlaxoSmithKline Plc last year. (Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)
The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based on two years overall survival in patients, the company said.
The combination was initially approved based on mid-stage data through the FDA's accelerated approval program, but the approval was contingent on data from late-stage trial.
Tafinlar and Mekinist are among cancer drugs Novartis had purchased from GlaxoSmithKline Plc last year. (Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.